Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH.

J Clin Oncol. 2019 Sep 18:JCO1901056. doi: 10.1200/JCO.19.01056. [Epub ahead of print]

PMID:
31532724
2.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang CJ, Yarchoan R, Cheever MA; Cancer Immunotherapy Trials Network (CITN)-12 Study Team.

JAMA Oncol. 2019 Jun 2. doi: 10.1001/jamaoncol.2019.2244. [Epub ahead of print]

PMID:
31154457
3.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
4.

Tuberculosis following PD-1 blockade for cancer immunotherapy.

Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, Nieva JJ, Cheever MA, Nghiem PT, Sharon E.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702.

PMID:
30651320
5.

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

Miller NJ, Church CD, Fling SP, Kulikauskas R, Ramchurren N, Shinohara MM, Kluger HM, Bhatia S, Lundgren L, Cheever MA, Topalian SL, Nghiem P.

J Immunother Cancer. 2018 Nov 27;6(1):131. doi: 10.1186/s40425-018-0450-7.

6.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

7.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

8.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

9.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

11.

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.

Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ Jr, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.

J Transl Med. 2012 Mar 15;10:48. doi: 10.1186/1479-5876-10-48.

12.

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

Cheever MA, Higano CS.

Clin Cancer Res. 2011 Jun 1;17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6.

13.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM.

Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.

14.

Translational Research Working Group developmental pathway for immune response modifiers.

Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG; Translational Research Working Group.

Clin Cancer Res. 2008 Sep 15;14(18):5692-9. doi: 10.1158/1078-0432.CCR-08-1266.

15.

Twelve immunotherapy drugs that could cure cancers.

Cheever MA.

Immunol Rev. 2008 Apr;222:357-68. doi: 10.1111/j.1600-065X.2008.00604.x. Review.

PMID:
18364014
16.

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.

Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, Pappen B, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA.

Mol Ther. 2006 Jun;13(6):1185-91. Epub 2006 Apr 11.

17.

Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants.

Mossman SP, Evans LS, Fang H, Staas J, Tice T, Raychaudhuri S, Grabstein KH, Cheever MA, Johnson ME.

Vaccine. 2005 May 20;23(27):3545-54.

PMID:
15855013
18.

Cancer vaccines and immunotherapies: emerging perspectives.

Henderson RA, Mossman S, Nairn N, Cheever MA.

Vaccine. 2005 Mar 18;23(17-18):2359-62.

PMID:
15755628
19.

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA.

J Clin Oncol. 2004 May 15;22(10):1916-25.

PMID:
15143085
20.

Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.

Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ.

J Immunol. 2003 Sep 1;171(5):2251-61.

21.
22.

HER2 dendritic cell vaccines.

Morse MA, Clay TM, Colling K, Hobeika A, Grabstein K, Cheever MA, Lyerly HK.

Clin Breast Cancer. 2003 Feb;3 Suppl 4:S164-72.

PMID:
12620155
23.

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG.

Clin Cancer Res. 2002 Nov;8(11):3407-18.

24.

Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera.

Day CH, Fanger GR, Retter MW, Hylander BL, Penetrante RB, Houghton RL, Zhang X, McNeill PD, Filho AM, Nolasco M, Badaro R, Cheever MA, Reed SG, Dillon DC, Watanabe Y.

Oncogene. 2002 Oct 10;21(46):7114-20.

25.

Designing HER2 vaccines.

Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA.

Semin Oncol. 2002 Jun;29(3 Suppl 11):53-61. Review.

PMID:
12138398
26.

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K.

J Clin Oncol. 2002 Jun 1;20(11):2624-32.

PMID:
12039923
27.
28.

WT1-specific serum antibodies in patients with leukemia.

Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, Cornellison CD, Vedvick TS, Skeiky YA, Cheever MA.

Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s.

PMID:
11300470
29.

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.

Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K.

Vaccine. 2001 Mar 21;19(17-19):2598-606.

PMID:
11257398
30.

Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.

Gaiger A, Reese V, Disis ML, Cheever MA.

Blood. 2000 Aug 15;96(4):1480-9.

PMID:
10942395
31.

Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression.

Bernhard H, Huseby ES, Hand SL, Lohmann M, Batten WY, Disis ML, Gralow JR, Meyer zum Büschenfelde KH, Ohlén C, Cheever MA.

Immunobiology. 2000 Apr;201(5):568-82.

PMID:
10834314
32.

Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis.

Villaret DB, Wang T, Dillon D, Xu J, Sivam D, Cheever MA, Reed SG.

Laryngoscope. 2000 Mar;110(3 Pt 1):374-81.

PMID:
10718422
33.

CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.

Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA.

Blood. 1999 Sep 15;94(6):2048-55.

PMID:
10477734
34.
35.
36.
37.

T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis.

Chen W, Chatta GS, Rubin WD, Clark JG, Hackman RC, Madtes DK, Ligitt DH, Kusunoki Y, Martin PJ, Cheever MA.

J Immunol. 1998 Jul 15;161(2):909-18.

38.
39.

HER-2/neu oncogenic protein: issues in vaccine development.

Disis ML, Cheever MA.

Crit Rev Immunol. 1998;18(1-2):37-45. Review.

PMID:
9419446
40.

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA.

J Clin Oncol. 1997 Nov;15(11):3363-7.

PMID:
9363867
41.

Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.

Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB, Weiner LM.

Cancer Immunol Immunother. 1997 Jul;44(5):265-72.

PMID:
9247561
42.

Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy.

Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA.

J Immunol. 1997 Jul 1;159(1):472-80.

PMID:
9200488
43.

Therapy with cultured T cells: principles revisited.

Cheever MA, Chen W.

Immunol Rev. 1997 Jun;157:177-94. Review.

PMID:
9255630
44.

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA.

Hum Immunol. 1997 Feb;52(2):109-18.

PMID:
9077559
45.

In vitro priming to tumor-associated proteins.

Hand SL, Bernhard H, Huseby ES, Rubin WD, Disis ML, Cheever MA.

Adv Exp Med Biol. 1997;417:503-9. Review. No abstract available.

PMID:
9286411
46.

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

Disis ML, Cheever MA.

Adv Cancer Res. 1997;71:343-71. Review.

PMID:
9111870
48.

Oncogenic proteins as tumor antigens.

Disis ML, Cheever MA.

Curr Opin Immunol. 1996 Oct;8(5):637-42. Review.

PMID:
8902388
49.

[Probability of vaccine therapy for pancreas cancer].

Takahashi M, Togou S, Yamaoka H, Ichikawa H, Shimada H, Cheever MA.

Gan To Kagaku Ryoho. 1996 Oct;23(12):1676-8. Japanese.

PMID:
8886043
50.

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.

Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA.

Blood. 1996 Jul 1;88(1):202-10.

PMID:
8704175

Supplemental Content

Loading ...
Support Center